Zhejiang Kanying Import & Export Co. Ltd 86--17169758851 kanyingexport@gmail.com
Inhibit dietary fat orlistat quick effect, high quality and large discount

Inhibit dietary fat orlistat quick effect, high quality and large discount

  • Product Name
  • CAS
  • Molecular Weight
  • Density
    1.0±0.1 G/cm3
  • Boiling Point
    615.9±30.0 °C At 760 MmHg
  • Molecular Formula
  • Melting Point
  • Point Of Flammability
    326.3±24.6 °C
  • Brand Name
    Kan Ying
  • Place Of Origin
  • Place of Origin
  • Brand Name
    Kan Ying
  • Minimum Order Quantity
  • Price
    To discuss
  • Packaging Details
  • Delivery Time
  • Payment Terms
    L/C, D/A, D/P, T/T, Western Union, MoneyGram,Dollars
  • Supply Ability

Inhibit dietary fat orlistat quick effect, high quality and large discount

Inhibit dietary fat orlistat quick effect, high quality and large discount


1,  Product title: Orlistat


2,  Product Description:


Promethazine hydrochloride is commonly used in tablets and injections. It is an antihistamine. Allergies to the skin mucosa, including chronic or seasonal allergic rhinitis, vasomotor rhinitis, allergic conjunctivitis, urticaria, angioneurotic edema, allergic reactions to blood or plasma products, and skin scratches; Motion sickness, prevention and treatment of motion sickness, seasickness, airsickness; Anesthesia and auxiliary treatment before and after surgery, including sedation, hypnosis, analgesia, antiemetic; Prevention and treatment of radiation sickness or drug - derived nausea, vomiting.


3,  Product parameter table:


Product name Orlistat
CAS no 96829-58-2
Density of 1.0±0.1 g/cm3
Boiling point 615.9±30.0 °C at 760 mmHg
Melting point <50ºC
Molecular formula C29H53NO5
Molecular weight 495.735
Flash point 326.3±24.6 °C
Precise quality 495.392365
PSA 81.70000
LogP 8.94
Appearance solid | white
Vapor pressure 0.0±1.8 mmHg at 25°C
Refractive index 1.470
Storage conditions 2-8°C
Water solubility DMSO: 19 mg/mL


4,  Product introduction


Orlistat capsule, western medicine name. It's an anti-obesity drug. To reduce the incidence of obesity-related risk factors and other obesity-related diseases, including hypercholesterolemia, type 2 diabetes, hypoglycemia, hyperinsulinemia, hypertension, and to reduce the amount of fat in the viscera.


5,orlistat  indications:


Ollistat belongs to lipase inhibitor kind of slimming medicine, it is lipstatin (lipstatin) hydration derivative, can reduce the absorption of food fat, so as to reduce weight. This product has strong and selective inhibition of gastric lipase and pancreatic lipase, and has no effect on other digestive enzymes (amylase, trypsin, chymotrypsin) and phospholipase, and does not affect the absorption of carbohydrates, proteins and phospholipids. The drug was not absorbed by gastrointestinal tract and the inhibition of lipase was reversible.
Orlistat inactivates the enzyme primarily in the gastrointestinal tract by covalently binding to serine residues at the active sites of gastric lipase and pancreatic lipase, inhibits the hydrolysis of triacylglycerol, and reduces the intake of mono-glycerol and free fatty acids, thereby controlling body weight. The pharmacological activity of orlistat was dose-dependent. A therapeutic dose of orlistat (120 mg/ d, tid, taken with meals) combined with a slightly low-calorie balanced diet reduced dietary fat absorption by 30%. Studies in normal-weight and obese volunteers have shown that orlistat is largely unabsorbed by the body and the plasma concentration of the drug is very low. 5 ng/ml. Generally, systemic absorption of orlistat at therapeutic doses is minimal and short-term treatment does not accumulate. In vitro experiments, the binding rate of orlistat to plasma proteins was as high as 99% (lipoprotein and albumin were the main binding proteins), and orlistat rarely bound to red blood cells. Studies in obese patients have shown that minimally absorbed orlistat has two major metabolites in plasma, M1(4-cyclolactone ring hydrolysate) and M3(M1 with an n-formylleucine lysate attached), accounting for 42% of total plasma concentrations. The inhibition of LIPase by M1 and M3 was very weak. Unabsorbed orlistat is excreted mainly in the stool, accounting for approximately 97% of the dose administered, of which 83% is proforma. Cumulative renal excretion of orlistat and its metabolites is less than 2%, and complete excretion (stool and urine) of the drug takes 3 to 5 days. Both M1 and M3 can be excreted by bile.


Inhibit dietary fat orlistat quick effect, high quality and large discount 0


6,  Pharmacological effects:


Adverse reactions
1. Rare elevated transaminase, alkaline phosphatase and severe hepatitis have been reported after orlistat use. There are cases of liver failure, some of which require a liver transplant or can lead to death. Rare allergic reactions have also been reported with orlistat, and the main clinical manifestations are pruritus, rash, urticaria, angoneeurotic edema, bronchospasm and anaphylaxis. Large herpes is very rare.

2. Post-marketing monitoring also found reports of pancreatitis.

3. Seizures have been reported in patients taking orlistat in combination with antiepileptic drugs. Hyperoxalate urine and oxalate nephropathy have been reported.

4. Post-marketing, patients treated with orlistat in combination with anticoagulants experienced a decrease in thrombin, an increase in INR (internationally standardized ratio), and changes in hemostatic parameters due to an imbalance in treatment with anticoagulants.

Clinical research Experience:

1. This product mainly causes gastrointestinal adverse reactions, which are related to the pharmacological effects of drugs to prevent the absorption of absorbed fat. Common adverse reactions are: oily spots, increased gastrointestinal exhaust, urgent sense of stool, fat (oil) stool, fat diarrhea, increased number of stool and fecal incontinence.

2, with the increase of dietary fat composition, the incidence of adverse reactions also increased. Patients should be informed of the possibility of gastrointestinal reactions and appropriate management, such as dietary modifications, especially fat control. A low-fat diet reduces the likelihood of gastrointestinal adverse events, which helps patients self-test and adjust their fat intake. These gastrointestinal adverse events are usually mild and transient, occurring early in treatment (the first 3 months), with most patients experiencing only transient adverse events.

3, usually in patients taking this product more acute gastrointestinal reactions are: abdominal pain/abdominal discomfort, flatulence, watery stools, soft stools, rectal pain/rectal discomfort, odontosis, gum disease. Other adverse events observed were upper respiratory tract infections, lower respiratory tract infections, influenza, headache, menstrual disorders, anxiety, fatigue, and urinary tract infections.

4. In a 4-year clinical trial, the distribution pattern of adverse events was similar to that reported in 1-2-year clinical studies, with a similar overall incidence of gastrointestinal related adverse events in the first year and decreasing year by year thereafter.


7, Pictures of the product:


Inhibit dietary fat orlistat quick effect, high quality and large discount 1